Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 565.0 and a stoploss at Rs 600 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 600.0 and a stoploss at Rs 555 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 520.0 and a stop loss at Rs 502 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 640.0 and a stop loss at Rs 550 from entry point.

Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 543.6 and a stop loss at Rs 559.4 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 634.0 and a stop loss at Rs 575 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 610.0 and a stop loss at Rs 565 from entry point.

Buy Sun Pharmaceutical Industries at a price target of Rs 530 and a stop loss at Rs 498 from entry point.

Buy Sun Pharmaceutical Industries at a price target of Rs 585 and a stop loss at Rs 553 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 580.0 and a stoploss at Rs 535 from entry point.

Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 562.0 and a stoploss at Rs 545 from entry point.

Buy Sun Pharmaceutical Industries at a price target of Rs 550 and a stop loss at Rs 520 from entry point.

Sell Sun Pharmaceutical Industries Ltd. at a price target of Rs 519 and a stop loss at Rs 588 from entry point.

Additionally in May earlier this year, ET had reported that MAPE Advisory Group was investing in the still yet-to-be launched Netmeds.com.

Pharma aggregator startup Netmeds.com has tied up with India Post as logistics partner for pan India delivery of medicines.

Online pharmacy Netmeds, which is backed by boutique investment firm MAPE Advisory Services is set to go live next week and targets a marke...

MAPE Advisory along with founder Pradeep Dadha are initially pumping in Rs 30 crore in the firm, with a commitment to increase it to Rs 60 ...